Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

503
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
503
Positron Emission Tomography01:29

Positron Emission Tomography

6.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.9K
Isotopes and Radioisotopes01:28

Isotopes and Radioisotopes

11.0K
In the early 1900s, English chemist Frederick Soddy realized that an element could have atoms with different masses that were chemically indistinguishable. These different types are called isotopes — atoms of the same element that differ in mass. Isotopes differ in mass because they have different numbers of neutrons but are chemically identical because they have the same number of protons. Soddy was awarded the Nobel Prize in Chemistry in 1921 for this discovery.
An isotope containing...
11.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

405
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Response to Interesting Image Titled "99mTc-FAPI-46 Scintigraphy and Radioligand Therapy With 177Lu-FAPI-2286 in Locally Advanced Epithelioid Sarcoma".

Clinical nuclear medicine·2026
Same author

Diagnostic Dilemma and Therapeutic Challenges in <i>EWSR1::PATZ1</i> Fusion Sarcomas: Insights From Two Patients.

International journal of surgical pathology·2026
Same author

Perirectal spacers and endorectal balloons in external beam radiotherapy for prostate cancer: a review of prospective studies.

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]·2026
Same author

Intestinal Low-Dose Radiation to Overcome PD-1 Resistance in Pediatric Relapsed/Refractory Hodgkin Lymphoma.

Pediatric blood & cancer·2026
Same author

Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.

International journal of radiation oncology, biology, physics·2026
Same author

68 Ga-DOTANOC PET/CT in a Case of Grade 1 Pancreatic NET With Renal Vein and Gonadal Vein Tumor Thrombus.

Clinical nuclear medicine·2026

Related Experiment Video

Updated: Jan 16, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

869

Theranostics and personalized radiopharmaceuticals.

Sushant Sushant1, Daya Nanad Sharma1, Surendra Kumar Saini1

  • 1Department of Radiation Oncology, IRCH, New Delhi, India.

Journal of Cancer Research and Therapeutics
|September 26, 2025
PubMed
Summary
This summary is machine-generated.

Personalized radiopharmaceuticals are advancing theranostics, merging diagnostics and therapeutics for tailored cancer care. This approach enables precise tumor targeting, real-time monitoring, and improved patient outcomes in oncology.

Keywords:
Nanobrachytherapypersonalised medicinepersonalised oncologyradiopharmaceuticalstheranostics

More Related Videos

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Related Experiment Videos

Last Updated: Jan 16, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
09:55

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules

Published on: October 4, 2024

869
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

9.2K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.5K

Area of Science:

  • * Molecular imaging and targeted therapy
  • * Personalized medicine and oncology

Background:

  • * Theranostics integrates diagnostic and therapeutic modalities for individualized patient care.
  • * The field merges imaging and treatment for enhanced precision in medicine.

Purpose of the Study:

  • * To review the impact of personalized radiopharmaceuticals on theranostics in oncology.
  • * To highlight the advancements in disease detection and targeted treatment strategies.

Main Methods:

  • * Review of current literature on personalized radiopharmaceuticals in theranostics.
  • * Analysis of the integration of diagnostic and therapeutic agents for molecular targeting.

Main Results:

  • * Personalized radiopharmaceuticals enable precise tumor targeting and characterization.
  • * Theranostics offers a unified approach for real-time monitoring of disease activity and treatment response.
  • * This integration minimizes adverse effects and enhances therapeutic efficacy.

Conclusions:

  • * Personalized radiopharmaceuticals are pivotal in advancing theranostics for individualized cancer treatment.
  • * The integration of theranostics aligns with precision medicine goals, improving patient outcomes and quality of life.